Solid Tumor Targeting CAR-T Development Services by Metabolic Reprogramming

Metabolic reprogramming serves as a fundamental determinant of T cell fate, directly influencing phenotypic polarization, functional durability, and long-term persistence by shifting energy metabolism and enhancing mitochondrial fitness. Creative Biolabs' Solid Tumor Targeting CAR-T Development Services by Metabolic Reprogramming are designed to overcome the immunosuppressive tumor microenvironment (TME) by systematically engineering CAR-T cells with optimized metabolic properties. We offer a unique integration of epigenetic-metabolic axis modulation, mitochondrial bioenergetics enhancement, and signaling pathway control, enabling the generation of T cells with robust stem-like memory characteristics, sustained effector function, and resilience to metabolic stress.

Introduction

Metabolic reprogramming constitutes a core physiological mechanism through which cells dynamically modulate their metabolic pathways to fulfill context-specific bioenergetic and biosynthetic requirements linked to functional specialization and differentiation. In CAR-T cell immunotherapy, steering T-cell metabolism away from glycolysis-driven exhaustion and toward mitochondrial oxidative phosphorylation (OXPHOS) is essential for fostering stem-cell memory traits, improving long-term persistence, and maintaining robust antitumor activity even within immunosuppressive tumor microenvironments.

Fig.1 Metabolic regulation of signaling in T cell fate.¹

Solid Tumor Targeting CAR-T Development Services by Metabolic Reprogramming at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Services by Metabolic Reprogramming offers a comprehensive strategy to resolve the twin challenges of CAR-T failure: rapid exhaustion during ex vivo culture and metabolic starvation in vivo. We provide functional engineering solutions that leverage the biological crosstalk between a T cell's metabolic state and its epigenetic fate, specifically aiming to enhance OXPHOS and enforce the memory phenotype.

Service Packages

Our service provides integrated metabolic reprogramming strategies to overcome T cell dysfunction in solid tumors.

Our Service Process

Required Starting Materials:

• T Cell Source: Peripheral Blood Mononuclear Cells (PBMCs) or leukapheresis products from the client.
• CAR Construct: The final lentiviral or retroviral vector sequence, including the chosen scFv and co-stimulatory domains.
• Target Antigen/TME Profile: Specific target antigen and any known metabolic or immunosuppressive features of the patient's tumor microenvironment.

Key steps:

Final Deliverables:

• Optimized Manufacturing Protocol and Quality Control Report: A validated, transferrable protocol for the production of the metabolically enhanced CAR-T product, including the final phenotypic and mitochondrial quality control panel.
• Comprehensive Metabolic Profile Data: Detailed data on T cell subset distribution, key exhaustion marker expression, OCR/ECAR metabolic flux analysis, and the expression levels of key genes.

Key Advantages

• Customized Metabolic Reprogramming: We implement tailored metabolic modulation protocols to precisely direct T cell differentiation toward your target phenotype, such as preferentially enriching for T_SCM or T_CM populations.
• Integrated Process & Pathway Engineering: Our platform integrates upstream and downstream process optimization, utilizing customized genetic constructs and selective small-molecule libraries to maximize both the yield and functional potency of TME-resistant CAR-T cells.
• Predictive Quality Assurance: Rigorous, process analytical techniques (PAT)-integrated quality control is mandatory, featuring Mito-Flux assays and epigenetic profiling to quantitatively verify a stable OXPHOS metabolic state and ensure product consistency and persistence before release.

FAQs

Why Choose Us?

Creative Biolabs pioneers metabolic reprogramming to overcome the core challenge in solid tumor CAR-T therapy: T cell dysfunction. We uniquely engineer durable, TME-resilient T cells by masterfully controlling the epigenetic-metabolic axes and critical signaling pathways. Our proven approach consistently yields superior T_SCM enrichment and potent, long-lasting anti-tumor efficacy.

Customer Reviews

"The implementation of Creative Biolabs' Solid Tumor Targeting CAR-T Development Services markedly enhanced T cell persistence in our preclinical models, culminating in a final T_SCM proportion exceeding 30%, a critical benchmark for sustained clinical efficacy. Metabolic profiling corroborated this outcome, confirming a definitive shift toward an OXPHOS-dominant state." Dr. Mar***a N.

"Creative Biolabs' Asparagine Metabolism Engineering strategy effectively addressed our primary challenge: T cell dysfunction in solid tumor models caused by nutrient scarcity. The resulting engineered cells maintained potent cytotoxic activity even under TME-mimetic culture conditions, significantly outperforming our conventional CAR-T constructs." Dr. Chr***s L.

"Prior inconsistent product quality, characterized by elevated PD-1/TIM-3 expression post-expansion, was resolved by adopting Creative Biolabs' PI3K Inhibitor Protocol. This approach consistently suppressed key exhaustion markers by over 40%, enabling reliable production of high-quality batches with robust and sustained in vivo anti-tumor activity." Dr. Sam***l K.

How to Contact Us?

Partner with our scientific team to initiate the design of a tailored, TME-resilient CAR-T therapeutic. We are ready to delve into the specifics of your CAR construct, tumor target, and intended metabolic profile to navigate your path to success.

Partner with us to translate your vision into a potent CAR-T therapy.

Reference

1. Van der Vreken, Arne et al. "Fueling CARs: metabolic strategies to enhance CAR T-cell therapy." Experimental hematology & oncology vol. 13,1 66. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s40164-024-00535-1.